Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: Short Bowel Syndrome, Intestinal Fistula, Crohn Disease, Intestinal Obstruction
Interventions: SMOFLipid, Intralipid; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dry Age-related Macular Degeneration
Interventions: GT005; Drug
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 45
States / cities: Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more

Conditions: Marburg Virus Disease
Interventions: PHV01, Placebo; Biological
Lead sponsor: Public Health Vaccines LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Lumbar Spinal Stenosis
Interventions: electric dry needling, manipulation, conventional physical therapy; Other
Lead sponsor: Alabama Physical Therapy & Acupuncture; Other
Eligibility: 50 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Canton, Georgia

Conditions: Venous Leg Ulcer
Interventions: TTAX01, Profore Compression Therapy, Cadexomer Iodine dressing; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Carlsbad, California • Sylmar, California • North Chicago, Illinois + 3 more

Conditions: Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma
Interventions: interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Protein Losing Enteropathy
Interventions: ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Glucagon, Insulin; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Nasal Valve Collapse, Nose Enhancement
Interventions: Low-temperature radio-frequency reshaping of autologous cartilage nasal and/or auricular cartilage; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Indianapolis, Indiana

Conditions: Childhood Obesity
Interventions: Grow Together peer group; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postpartum Depression
Interventions: Use of internet based social marketing intervention, No use of social media; Other
Lead sponsor: University of Louisville; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Carrollton, Kentucky • Covington, Kentucky • Elizabethtown, Kentucky + 5 more

Conditions: Obesity
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,853 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 74
States / cities: Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 59 more

Conditions: Sickle Cell Disease
Interventions: Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand); Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Irvine, California • Indianapolis, Indiana

Conditions: Diabetes Mellitus, Type 1
Interventions: Medium chain fatty acid (Octanoic and Decanoic acid), Splenda (Placebo Control); Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Dysphonia Resulting From Vocal Fold Scarring, Age-related Dysphonia
Interventions: Azficel-T (autologous fibroblasts), Placebo; Biological · Drug
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Stanford, California • New York, New York

Conditions: Depression
Interventions: VNS Therapy; Device
Lead sponsor: Cyberonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 26
States / cities: Tucson, Arizona • Sacramento, California • Marietta, Georgia + 21 more

Conditions: Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
Interventions: ASP3772, PCV13, PPSV23; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Banning, California • San Diego, California • San Marcos, California + 21 more

Conditions: Depression, Adolescent Health
Interventions: Treatment as usual, Behavioral health intervention; Other · Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 18 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Autistic Disorder, Autism Spectrum Disorder, Child Development Disorders, Pervasive, Neurodevelopmental Disorders, Mental Disorders, Asperger's Syndrome, Neurobehavioral Manifestations, Nervous System Diseases
Interventions: SQUED™ series 28.1 home-use; Device
Lead sponsor: American Federation of Medical Synergetics; Other
Eligibility: 1 Month to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Adapted Family History Screening Program; Other
Lead sponsor: Emory University; Other
Eligibility: 25 Years and older · Female only
Enrollment: 3,209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer, Cervical Cancer
Interventions: SM-LHW, PN-LHW; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Otitis
Interventions: Conventional otoscope, Smartphone otoscope; Other
Lead sponsor: Emory University; Other
Eligibility: 6 Months to 18 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Concussion, Brain
Interventions: [11C] PiB, [18F] PBR111, [18F] Flortaucipir; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 70 Years · Male only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 3
States / cities: Waltham, Massachusetts • Chapel Hill, North Carolina • Milwaukee, Wisconsin

Search by objective public record fields.

Intralipid Versus SMOFlipid in HPN Patients

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects

Dry Needling and Spinal Manipulation vs. Conventional PT for Lumbar Spinal Stenosis

Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)

Vaccine Therapy in Treating Patients With Metastatic Cancer

Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

Physiologic Response to Glucagon at Varying Insulin Levels

Cartilage Remodeling Using Low-Temperature Radiofrequency for Nasal Airway Reconstruction

Healthy Growth Abbreviated Pilot Study

Social Media, Teen Moms and PPD

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Acupressure in Patients With Sickle Cell Disease

Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Reducing Health Risk Behavior and Improving Health in Adolescents With Depression

SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City

Community Pediatric Acceptability Study (CPAS)

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NFL LONG Prospective Study